A significant advancement in breast cancer care may soon emerge through artificial intelligence (AI). Researchers at Ataraxis AI, in collaboration with U.S. medical institutions, have developed an AI model that predicts disease progression with greater accuracy than current hospital tests.
Breast cancer, one of the most common cancers among women, can also affect men. Its varied progression rates complicate medical decisions, as accurate assessment is crucial for administering appropriate treatment. Current tests, such as Oncotype DX, while helpful, have limitations in precision.
Ataraxis AI's model utilizes extensive databases of tumor images and patient data to provide more reliable progression estimates. By employing multiple complementary AI algorithms, the model aggregates results to minimize errors, achieving up to 30% greater accuracy compared to standard tools.
Initial tests involving 3,500 patients indicate that this technology could transform breast cancer management. If confirmed in clinical trials, it may lead to personalized treatment strategies for patients, with potential applications in other cancer types as well.
Ataraxis AI plans to develop additional tools based on this model and aims to make it available as software for hospitals next year, marking a potential turning point in breast cancer patient care.